DEBRA Research GmbH, a global non-profit organization working to advance R&D for Epidermolysis Bullosa (EB), and Dermaliq Therapeutics, Inc., a clinical-stage dermatology company developing next-gen topical therapies, entered a strategic, non-exclusive collaboration to advance cutaneous drug delivery into the skin for EB.  The companies will initially focus on improving wound-healing and anti-itch therapies, and developing prophylactic therapies for EB. As part of the agreement, DEBRA Res...